• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS).

作者信息

Egeberg Alexander, Thyssen Jacob P

机构信息

Department of Dermatology, Copenhagen University Hospital - Bispebjerg, Copenhagen, Denmark.

Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

出版信息

Br J Dermatol. 2023 May 24;188(6):793-794. doi: 10.1093/bjd/ljad039.

DOI:10.1093/bjd/ljad039
PMID:36797979
Abstract
摘要

相似文献

1
Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS).在美国食品药品监督管理局不良事件报告系统（FAERS）中观察到，使用司库奇尤单抗后脑血管意外报告有所增加。
Br J Dermatol. 2023 May 24;188(6):793-794. doi: 10.1093/bjd/ljad039.
2
Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics.探索 FDA 不良事件报告系统，以生成监测疾病特征的假设。
Clin Pharmacol Ther. 2014 May;95(5):496-8. doi: 10.1038/clpt.2014.17. Epub 2014 Jan 21.
3
Letter to the editor concerning the article: 'Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA adverse event reporting system (FAERS)'.致编辑的信，关于文章：“司库奇尤单抗潜在的脑血管意外信号：美国食品药品监督管理局不良事件报告系统（FAERS）的不成比例性分析”
Br J Clin Pharmacol. 2023 Aug;89(8):2639-2641. doi: 10.1111/bcp.15746. Epub 2023 Apr 27.
4
The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.韦伯效应与美国食品药品监督管理局不良事件报告系统（FAERS）：对2006年至2010年批准的62种药物的分析
Drug Saf. 2014 Apr;37(4):283-94. doi: 10.1007/s40264-014-0150-2.
5
Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.FDA 收到的自发性上市后不良事件报告中关于血栓栓塞事件与 JAK 抑制剂的分析
Drug Saf. 2018 Apr;41(4):357-361. doi: 10.1007/s40264-017-0622-2.
6
Miscategorization of Deaths in the US Food and Drug Administration Adverse Events Database.美国食品和药物管理局不良事件数据库中死亡病例的分类错误。
JAMA Intern Med. 2020 Jan 1;180(1):147-148. doi: 10.1001/jamainternmed.2019.4030.
7
Adverse drug and device reactions in the oral cavity: surveillance and reporting.口腔中的药物和器械不良反应：监测与报告
J Am Dent Assoc. 2013 Sep;144(9):1014-21. doi: 10.14219/jada.archive.2013.0228.
8
Sequential surveillance for drug safety in a regulatory environment.监管环境下药品安全性的序贯监测。
Pharmacoepidemiol Drug Saf. 2018 Jul;27(7):707-712. doi: 10.1002/pds.4407. Epub 2018 Mar 5.
9
Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS).激励报告：美国食品药品监督管理局发布的警报对不良事件报告系统（FAERS）的影响。
Drug Saf. 2014 Nov;37(11):971-80. doi: 10.1007/s40264-014-0225-0.
10
Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.利用食品和药物管理局不良事件报告系统（FAERS）数据库，采用不匀称性分析识别以前未知的药物相关心律失常原因。
J Cardiovasc Pharmacol Ther. 2021 Jul;26(4):341-348. doi: 10.1177/1074248420984082. Epub 2021 Jan 6.

引用本文的文献

1
Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events.白细胞介素-17抑制剂与早期主要不良心血管事件
JAMA Dermatol. 2025 Sep 3. doi: 10.1001/jamadermatol.2025.2972.
2
Cardiovascular safety of Janus kinase inhibitors: A pharmacovigilance study from 2012-2023.Janus激酶抑制剂的心血管安全性：一项2012年至2023年的药物警戒研究。
PLoS One. 2025 May 12;20(5):e0322849. doi: 10.1371/journal.pone.0322849. eCollection 2025.
3
Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-α, IL-12/23, IL-17, and IL-23: A population-based retrospective cohort study.
接受靶向TNF-α、IL-12/23、IL-17和IL-23生物制剂治疗的银屑病患者的心血管疾病风险：一项基于人群的回顾性队列研究。
PLoS Med. 2025 Apr 17;22(4):e1004591. doi: 10.1371/journal.pmed.1004591. eCollection 2025 Apr.
4
Osteonecrosis of the jaw in patients with clear cell renal cell carcinoma treated with targeted agents: a case series and large-scale pharmacovigilance analysis.接受靶向药物治疗的透明细胞肾细胞癌患者颌骨骨坏死：病例系列及大规模药物警戒分析
Front Pharmacol. 2024 Oct 29;15:1309148. doi: 10.3389/fphar.2024.1309148. eCollection 2024.
5
Do interleukin-17 and interleukin-23 inhibitors alter the coagulation parameters in psoriasis patients?: A retrospective study.白细胞介素-17 和白细胞介素-23 抑制剂是否会改变银屑病患者的凝血参数？一项回顾性研究。
Arch Dermatol Res. 2024 Sep 11;316(8):613. doi: 10.1007/s00403-024-03369-3.
6
Electrolyte disorders induced by six multikinase inhibitors therapy for renal cell carcinoma: a large-scale pharmacovigilance analysis.六种多激酶抑制剂治疗肾癌引起的电解质紊乱：大规模药物警戒分析。
Sci Rep. 2024 Mar 7;14(1):5592. doi: 10.1038/s41598-024-56335-4.
7
Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data.生物制剂治疗银屑病的主要心血管事件：FAERS 数据的 19 年真实世界分析。
Front Immunol. 2024 Feb 7;15:1349636. doi: 10.3389/fimmu.2024.1349636. eCollection 2024.
8
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS).司库奇尤单抗在真实世界环境中的有效性、耐受性和药物留存率：一项为期三年的回顾性多中心研究-IL PSO（意大利银屑病概况）
J Clin Med. 2024 Jan 16;13(2):495. doi: 10.3390/jcm13020495.
9
Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis.GLP-1 受体激动剂的自杀/自残的上市后安全性概况：一项真实世界的药物警戒分析。
Eur Psychiatry. 2023 Nov 30;66(1):e99. doi: 10.1192/j.eurpsy.2023.2474.
10
Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database.司库奇尤单抗治疗银屑病和关节病型银屑病的药物警戒：来自欧洲药品管理局药物警戒数据库的真实世界数据
Pharmaceutics. 2023 Jul 11;15(7):1933. doi: 10.3390/pharmaceutics15071933.